Publication | Closed Access

Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis

VaccinationHepatologyViral HepatitisRoutine Antiviral ProphylaxisImmunologyHepatitis BHepatitisRituximab-containing Combination ChemotherapyHepatitis B VirusImmunotherapyMedicine